Emerging experimental therapeutics for bipolar disorder: insights from the molecular and cellular actions of current mood stabilizers

被引:0
作者
T D Gould
J A Quiroz
J Singh
C A Zarate
H K Manji
机构
[1] Laboratory of Molecular Pathophysiology,
[2] National Institute of Mental Health,undefined
来源
Molecular Psychiatry | 2004年 / 9卷
关键词
depression; mania; pharmacology; manic-depressive illness; neurotrophic factors; valproic acid; PAP phosphatase; pramipexole; zinc;
D O I
暂无
中图分类号
学科分类号
摘要
Bipolar disorder afflicts approximately 1–3% of both men and women, and is coincident with major economic, societal, medical, and interpersonal consequences. Current mediations used for its treatment are associated with variable rates of efficacy and often intolerable side effects. While preclinical and clinical knowledge in the neurosciences has expanded at a tremendous rate, recent years have seen no major breakthroughs in the development of novel types of treatment for bipolar disorder. We review here approaches to develop novel treatments specifically for bipolar disorder. Deliberate (ie not by serendipity) treatments may come from one of two general mechanisms: (1) Understanding the mechanism of action of current medications and thereafter designing novel drugs that mimics these mechanism(s); (2) Basing medication development upon the hypothetical or proven underlying pathophysiology of bipolar disorder. In this review, we focus upon the first approach. Molecular and cellular targets of current mood stabilizers include lithium inhibitable enzymes where lithium competes for a magnesium binding site (inositol monophosphatase, inositol polyphosphate 1-phosphatase, glycogen synthase kinase-3 (GSK-3), fructose 1,6-bisphosphatase, bisphosphate nucleotidase, phosphoglucomutase), valproate inhibitable enzymes (succinate semialdehyde dehydrogenase, succinate semialdehyde reductase, histone deacetylase), targets of carbamazepine (sodium channels, adenosine receptors, adenylate cyclase), and signaling pathways regulated by multiple drugs of different classes (phosphoinositol/protein kinase C, cyclic AMP, arachidonic acid, neurotrophic pathways). While the task of developing novel medications for bipolar disorder is truly daunting, we are hopeful that understanding the mechanism of action of current mood stabilizers will ultimately lead clinical trials with more specific medications and thus better treatments those who suffer from this devastating illness.
引用
收藏
页码:734 / 755
页数:21
相关论文
共 945 条
  • [81] Ray WJ(2003)Inhibition of cyclin-dependent kinases GSK-3beta and CK1 by hymenialdisine, a marine sponge constituent Pol J Pharmacol 55 1143-300
  • [82] Szymanki ES(2001)Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25 Brain Res Bull 55 297-164
  • [83] Ng L(2003)Inhibitors of glycogen synthase kinase-3: future therapy for unmet medical needs Brain Res Bull 61 159-406
  • [84] Masuda CA(2000)Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation Pol J Pharmacol 52 403-685
  • [85] Xavier MA(2002)Effect of zinc supplementation on antidepressant therapy in unipolar depression: a preliminary placebo-controlled study Pol J Pharmacol 54 681-2486
  • [86] Mattos KA(1980)Antidepressant-like properties of zinc in rodent forced swim test J Biol Chem 255 2481-4321
  • [87] Galina A(1976)Antidepressant-like effects of acute and chronic treatment with zinc in forced swim test and olfactory bulbectomy model in rats J Biol Chem 251 4315-8920
  • [88] Montero-Lomeli M(1995)Zinc exhibits an antidepressant-like effect in the forced swimming test in mice Proc Natl Acad Sci USA 92 8916-3043
  • [89] Klein PS(1996)Interaction of zinc with antidepressants in the forced swimming test in mice Biochemistry 35 3038-2058
  • [90] Melton DA(2003)Purification and properties of liver fructose 1,6-bisphosphatase from C57BL/KsJ normal and diabetic mice Bioorg Med Chem Lett 13 2055-16039